Skip to main content
SpringerLink
Log in

Outcome of patients with malignant glioma and synchronous or metachronous non-central nervous system primary neoplasms

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Patients with malignant glioma who are also diagnosed with one or more primary neoplasms of other organs present a unique challenge in both determining prognosis and clinical management. The overlapping impact of the malignancies and their treatment result in confounding variables that may adversely affect optimal management of such patients. Additionally, the glioma-related characteristics and survival outcome of these patients is not well-defined. In this retrospective chart and data review from our longitudinal database, we identified patients with malignant glioma including anaplastic glioma and glioblastoma, diagnosed between January 2005 and June 2011, who were also diagnosed with other non-CNS primary neoplasms. Patients with known genetic syndromes were excluded. The data was analyzed to determine the clinical characteristics and glioma-related survival. A total of 204 patients with malignant glioma (165 glioblastoma and 39 anaplastic glioma) were identified. There was no significant difference in the overall survival or progression-free survival between patients with malignant glioma plus non-CNS primary neoplasm when compared with patients with malignant glioma only. In patients with glioblastoma and non-CNS malignancy, the duration between diagnosis of glioblastoma and non-CNS neoplasms did not significantly alter glioma-related survival. Patients with malignant glioma who were diagnosed with other non-CNS malignancy have survival outcome comparable to those with malignant glioma only. The duration between diagnosis of glioblastoma and diagnosis of non-CNS neoplasms did not affect survival. Further prospective studies specifically addressing survival and molecular characteristics of patients with malignant glioma plus non-CNS cancers are recommended.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Frodin JE, Ericsson J, Barlow L (1997) Multiple primary malignant tumors in a national cancer registry. Acta Oncol 36(5):465–469

    Article  PubMed  CAS  Google Scholar 

  2. Nagane M, Shibui S, Nishikawa R et al (1996) Triple primary malignant neoplasms including a malignant brain tumor: report of two cases and review of the literature. Surg Neurol 45(3):219–229

    Article  PubMed  CAS  Google Scholar 

  3. Piccirilli M, Salvati M, Bistazzoni S et al (2005) Glioblastoma multiforme and breast cancer: report on 11 cases and clinico-pathological remarks. Tumori 91(3):256–260

    PubMed  Google Scholar 

  4. Pöyhönen L, Heikkinen J, Vehkalahti I (1979) Two different primary tumours of the brain in a patient with breast cancer. Eur J Nucl Med 4(6):483–484

    Article  PubMed  Google Scholar 

  5. Lamaida E, Caputi F, Rapanà A, Bracale C, Graziussi G (1996) Waldenström’s macroglobulinemia associated with glioblastoma. A case report. Rev Neurol 152(10):637–639

    PubMed  CAS  Google Scholar 

  6. Freedman RA, Wirth LJ, Chirieac LR et al (2007) Glioblastoma in a patient with early-stage tonsil cancer. J Clin Oncol 25(19):2848–2850

    Article  PubMed  Google Scholar 

  7. Moertel CG (1964) Incidence and significance of multiple primary malignant neoplasms. Ann N Y Acad Sci 114:886–895

    Article  Google Scholar 

  8. Mariotto AB, Rowland JH, Ries LA et al (2007) Multiple cancer prevalence: a growing challenge in long-term survivorship. Cancer Epidemiol Biomark Prev 16(3):566–571

    Article  Google Scholar 

  9. Hayashi K, Ohtsuki Y, Sonobe H et al (1987) An autopsy case of triple primary cancers consisting of glioblastoma multiforme of the pons, colon cancer and rectal carcinoid–a statistical analysis of cases of brain tumor combined with other primary cancers in Japan autopsy annuals. Gan No Rinsho 33(14):1846–1853

    PubMed  CAS  Google Scholar 

  10. Aung L, Gorlick RG, Shi W et al (2002) Second malignant neoplasms in long-term survivors of osteosarcoma: Memorial Sloan-Kettering Cancer Center experience. Cancer 95(8):1728–1734

    Article  PubMed  Google Scholar 

  11. Elkabets M, Gifford AM, Scheel C et al (2011) Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice. J Clin Invest 121:784–799

    Article  PubMed  CAS  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neuro-oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Mohamed A. Hamza, Carlos Kamiya-Matsuoka & Vinay K. Puduvalli

  2. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Diane Liu & Ying Yuan

  3. OhioHealth Riverside Hospital, Columbus, OH, USA

    Mohamed A. Hamza

  4. Division of Neuro-oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA

    Vinay K. Puduvalli

Authors
  1. Mohamed A. Hamza
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carlos Kamiya-Matsuoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Diane Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ying Yuan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Vinay K. Puduvalli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohamed A. Hamza.

Ethics declarations

Conflict of interest

The authors declare that they do not have conflict of interest.

Electronic supplementary material

Below is the link to the electronic supplementary material.

11060_2015_1992_MOESM1_ESM.tif

Figure S1: Kaplan-Meier estimates of overall survival (OS) by anaplastic glioma with non-CNS neoplasms (grey line) and anaplastic glioma only (black line). Supplementary material 1 (TIFF 735 kb)

11060_2015_1992_MOESM2_ESM.tif

Figure S2: Kaplan-Meier estimates of progression-free survival (PFS) by glioblastoma with non-CNS neoplasms diagnosed within the period of 4 years before to 3 months after diagnosis with glioblastoma (broken line) and those who were diagnosed with non-CNS neoplasms more than 4 years before diagnosis of glioblastoma (black line). Supplementary material 2 (TIFF 645 kb)

Supplementary material 3 (DOCX 18 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hamza, M.A., Kamiya-Matsuoka, C., Liu, D. et al. Outcome of patients with malignant glioma and synchronous or metachronous non-central nervous system primary neoplasms. J Neurooncol 126, 527–533 (2016). https://doi.org/10.1007/s11060-015-1992-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-015-1992-x

Keywords

Search

Navigation